Thus, inhibition of DLK1 could be a strategy to reduce resistance to chemotherapy in ACC, particularly the EDP (etoposide, doxorubicin, cisplatin) regimen, which includes two chemotherapeutic drugs known to be ABCB1 transport substrates (etoposide and doxorubicin). The gene discussed is DLK1; the disease is adrenal cortex carcinoma.